Ista Vitrase NDA To Committee March 17; User Fee Goal April 8
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ista Pharmaceuticals’ NDA for the vitreous hemorrhage treatment Vitrase is based on two studies that show benefit on a secondary endpoint but do not reach statistical significance for the primary endpoint.
You may also be interested in...
Ista Vitrase Could Get Restricted Vitreous Hemorrhage Indication, Firm Says
Approval of Ista’s Vitrase in vitreous hemorrhage would likely be restricted to patients with diabetic retinopathy as an underlying cause, Ista suggested.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product